Evidence map›Paper›PMID 26053033›Full record

ArticleOncogenesis2015

Kruppel-like factor 4 signals through microRNA-206 to promote tumor initiation and cell survival.

C-C Lin, S B Sharma, M K Farrugia, S L McLaughlin, R J Ice, Y V Loskutov, E N Pugacheva, K M Brundage, D Chen, J M Ruppert

Open access · goldAbstract read
In one paragraph

Article in Oncogenesis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Circulating miRs-183-5p, -206-3p and -381-3p may serve as novel biomarkers for 4,4'-methylene diphenyl diisocyanate exposure.Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2019
    Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

C-C Lin1] Department of Biochemistry, West Virginia University, School of Medicine, Morgantown, WV, USA [2] The Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA.
S B Sharma1] Department of Biochemistry, West Virginia University, School of Medicine, Morgantown, WV, USA [2] Program in Cancer Cell Biology, West Virginia University, Morgantown, WV, USA.
M K Farrugia1] Department of Biochemistry, West Virginia University, School of Medicine, Morgantown, WV, USA [2] Program in Cancer Cell Biology, West Virginia University, Morgantown, WV, USA.
S L McLaughlinThe Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA.
R J Ice1] Department of Biochemistry, West Virginia University, School of Medicine, Morgantown, WV, USA [2] Program in Cancer Cell Biology, West Virginia University, Morgantown, WV, USA.
Y V Loskutov1] Department of Biochemistry, West Virginia University, School of Medicine, Morgantown, WV, USA [2] Program in Cancer Cell Biology, West Virginia University, Morgantown, WV, USA.
E N Pugacheva1] Department of Biochemistry, West Virginia University, School of Medicine, Morgantown, WV, USA [2] The Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA.
K M BrundageThe Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA.
D ChenDivision of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
J M Ruppert1] Department of Biochemistry, West Virginia University, School of Medicine, Morgantown, WV, USA [2] The Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA.
West Virginia University · USUniversity of Alabama at Birmingham · US

Funding

WV INBRE: The Inhibitor of Growth Family Member 4 (ING4) inhibits L-Type Amino Acid Transporter 1 (LAT1) expression to suppress Breast CancerP20GM103434 · NIGMS · MARSHALL UNIVERSITY · PI GARY O RANKIN · 2012 to 2026
$61.1M
THE ROLE OF HEF1 PROTEIN IN INVASION OF METASTATIC BREAST CANCERP20RR016440 · NCRR · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2001 to 2010
$22.8M
West Virginia Flow Cytometry Core FacilityP30GM103488 · NIGMS · WEST VIRGINIA UNIVERSITY · PI GIBSON, LAURA F. · 2012 to 2016
$4.8M
The role of HEF1 protein in division and invasion of metastatic breast cancerR01CA148671 · NCI · WEST VIRGINIA UNIVERSITY · PI PUGACHEVA, ELENA NIKOLAEVNA · 2010 to 2020
$3.2M
Klf4 in tumor initiation and maintenance of squamous cell carcinomaR01CA127405 · NCI · WEST VIRGINIA UNIVERSITY · PI RUPPERT, JOHN MICHAEL · 2007 to 2011
$1.4M
COBRE FOR SIGNAL TRANSDUCTION AND CANCER PHASE IIIP30RR032138 · NCRR · WEST VIRGINIA UNIVERSITY · PI GIBSON, LAURA F. · 2011 to 2011
$1.1M
Visual Sonics Vevo 2100 Imaging SystemS10RR026378 · NCRR · WEST VIRGINIA UNIVERSITY · PI MARTIN, KAREN H · 2010 to 2010
$454k
BECTON-DICKINSON FACSARIA FLOW CYTOMETER: SARCOPENIAS10RR020866 · NCRR · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2006 to 2006
$425k
Special Becton Dickinson Fortessa Flow CytometerS10OD016165 · OD · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2013 to 2013
$384k
NCI NIH HHS R01 CA127405NCI NIH HHS R01 CA148671NCRR NIH HHS P20 RR016440NCRR NIH HHS P30 RR032138NCRR NIH HHS S10 RR020866NCRR NIH HHS S10 RR026378NIGMS NIH HHS P20 GM103434NIGMS NIH HHS P30 GM103488NIH HHS S10 OD016165
6 · The paper itself

Abstract

Tumor cell heterogeneity poses a major hurdle in the treatment of cancer. Mammary cancer stem-like cells (MaCSCs), or tumor-initiating cells, are highly tumorigenic sub-populations that have the potential to self-renew and to differentiate. These cells are clinically important, as they display therapeutic resistance and may contribute to treatment failure and recurrence, but the signaling axes relevant to the tumorigenic phenotype are poorly defined. The zinc-finger transcription factor Kruppel-like factor 4 (KLF4) is a pluripotency mediator that is enriched in MaCSCs. KLF4 promotes RAS-extracellular signal-regulated kinase pathway activity and tumor cell survival in triple-negative breast cancer (TNBC) cells. In this study, we found that both KLF4 and a downstream effector, microRNA-206 (miR-206), are selectively enriched in the MaCSC fractions of cultured human TNBC cell lines, as well as in the aldehyde dehydrogenase-high MaCSC sub-population of cells derived from xenografted human mammary carcinomas. The suppression of endogenous KLF4 or miR-206 activities abrogated cell survival and in vivo tumor initiation, despite having only subtle effects on MaCSC abundance. Using a combinatorial approach that included in silico as well as loss- and gain-of-function in vitro assays, we identified miR-206-mediated repression of the pro-apoptotic molecules programmed cell death 4 (PDCD4) and connexin 43 (CX43/GJA1). Depletion of either of these two miR-206-regulated transcripts promoted resistance to anoikis, a prominent feature of CSCs, but did not consistently alter MaCSC abundance. Consistent with increased levels of miR-206 in MaCSCs, the expression of both PDCD4 and CX43 was suppressed in these cells relative to control cells. These results identify miR-206 as an effector of KLF4-mediated prosurvival signaling in MaCSCs through repression of PDCD4 and CX43. Consequently, our study suggests that a pluripotency factor exerts prosurvival signaling in MaCSCs, and that antagonism of KLF4-miR-206 signaling may selectively target the MaCSC niche in TNBC.

Identifiers

PMID26053033
PMCPMC4753526
OpenAlexW1592420296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.